Effectiveness of the Selective Serotonin Reuptake Inhibitor,Citalopram (Cipralex), in Prurigo Nodularis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00532519|
Recruitment Status : Unknown
Verified September 2007 by Hadassah Medical Organization.
Recruitment status was: Not yet recruiting
First Posted : September 20, 2007
Last Update Posted : September 20, 2007
Prurigo nodularis (PN) is a common dermatological disorder, manifested as scaly nodules which appear mainly on the extensor surfaces of the limbs. PN may appear secondarily to skin scratching in chronic hepatitis, liver cirrhosis, uremia, hypothyroidism etc. Nevertheless, in many cases no underlying physical disease is present. According to the literature, in fifty percent of the patients there is co-morbidity with depression, anxiety or somatoform disorders.
We hypothesize that a group of these patients may benefit from antidepressant therapy.
|Condition or disease||Intervention/treatment||Phase|
|Prurigo Nodularis||Drug: citalopram (cipralex)||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
- Drug: citalopram (cipralex)
10-20 mg/day, for 12 weeks.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00532519
|Contact: Liran Horev, MD||OO97226777111||LIRAN_CH@BEZEQINT.NET|
|Principal Investigator:||liran horev, md||Hadassah Medical Organization|
|Principal Investigator:||rena cooper-kazaz, md||Hadassah Medical Organization|